natgillin/translations-raw huggingface dataset:
What EVOTAZ looks like and contents of the pack EVOTAZ tablets are pink, oval, biconvex, film coated tablet of approximate dimensions of 19 mm x 10.4 mm, debossed on one side with "3641" and plain-faced on the other side of the tablet. 
EVOTAZ tablete su ružičaste, ovalne, bikonveksne, filmom obložene tablete dimenzija približno 19 mm x 10,4 mm, s utisnutom oznakom "3641" na jednoj strani i bez oznake na drugoj strani tablete.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co-administration with EVOTAZ may result in increased concentrations. 
Metabolizam simvastatina i lovastatina jako ovisi o CYP3A4 pa istodobna primjena s lijekom EVOTAZ može povisiti njihove koncentracije.
In study GS-US-216-0114, the mean increase from baseline in CD4+ cell count at weeks 48 and 144 were 213 and 310 cells/mm3 in patients receiving atazanavir boosted with cobicistat and 219 and 332 cells/mm3 in patients receiving atazanavir boosted with ritonavir, respectively. 
U ispitivanju GS-US-216-0114, srednje povećanje broja CD4+ stanica od početne vrijednosti u 48 odnosno 144. tjednu iznosilo je 213 odnosno 310 stanica/mm3 u bolesnika liječenih atazanavirom pojačanim kobicistatom te 219 odnosno 332 stanice/mm3 u bolesnika liječenih atazanavirom pojačanim ritonavirom.
No dosage adjustment is necessary if methadone is co-administered with EVOTAZ. 
Nije potrebno prilagođavati dozu kada se metadon primjenjuje istodobno s lijekom EVOTAZ.
Co-administration of EVOTAZ and rifabutin is not recommended. 
Ne preporučuje se istodobna primjena lijeka EVOTAZ i rifabutina.
f Plus background regimen of emtricitabine 200 mg and tenofovir DF 300 mg fixed-dose combination. 
f Plus osnovni režim liječenja fiksnom kombinacijom emtricitabina u dozi od 200 mg i tenofovira DFu dozi od
Cobicistat is a weak CYP2D6 inhibitor and is metabolised to a minor extent by CYP2D6. 
Kobicistat je slab inhibitor CYP2D6 i u manjoj se mjeri metabolizira putem CYP2D6.
Alternative antiretroviral therapy to EVOTAZ may be considered if jaundice or scleral icterus is unacceptable to a patient. 
Može se razmotriti primjena neke druge antiretrovirusne terapije umjesto lijeka EVOTAZ ako su žutilo kože ili bjeloočnica bolesniku neprihvatljivi.
If drospirenone/ethinyloestradiol is coadministered with atazanavir/cobicistat, clinical monitoring is recommended due to the potential for hyperkalemia. 
Ako se drospirenon/etinilestradiol primjenjuje istodobno s atazanavir/kobicistatom preporučuje se kliničko praćenje zbog moguće hiperkalemije.
There are no pharmacokinetic data regarding the use of EVOTAZ in patients with hepatic impairment. 
Nema farmakokinetičkih podataka o primjeni lijeka EVOTAZ u bolesnika s oštećenjem jetrene funkcije.
No data are available on the pharmacokinetics of atazanavir and cobicistat in combination in paediatric patients. 
Nema dostupnih podataka o farmakokinetici kombinacije atazanavira i kobicistata u pedijatrijskih bolesnika.
It is unknown if cobicistat/metabolites are excreted in human milk. 
Nije poznato izlučuju li se kobicistat/njegovi metaboliti u majčino mlijeko.
Higher concentrations could potentiate tenofovir-associated adverse reactions, including renal disorders. 
Povišene koncentracije mogu potencirati nuspojave povezane s primjenom tenofovira, uključujući bubrežne poremećaje.
Co-administration with EVOTAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism. 
Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije inhibitora PDE5 i pojačati nuspojave povezane s PDE5, uključujući hipotenziju, poremećaje vida i prijapizam.
Animal studies do not indicate direct or indirect harmful effects of cobicistat with respect to reproductive toxicity (see section 5.3). 
Ispitivanja na životinjama ne ukazuju ni na kakve izravne ni neizravne štetne učinke kobicistata na reprodukciju (vidjeti dio 5.3).
Tablet core - microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), sodium starch glycolate, crospovidone (E1202), stearic acid (E570), magnesium stearate (E470b), hydroxypropyl cellulose (E463), silicon dioxide (E551) Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172) 
Jezgra tableta - mikrokristalična celuloza (E460(i)), umrežena karmelozanatrij (E468), natrijev škroboglikolat, krospovidon (E1202), stearatna kiselina (E570), magnezijev stearat (E470b), hidroksipropilceluloza (E463), silicijev dioksid (E551) Film ovojnica - hipromeloza (hidroksipropilmetilceluloza, E464), titanijev dioksid (E171), talk (E553b), triacetin (E1518), crveni željezov oksid (E172)
Co-administration of EVOTAZ with medicinal products that are moderate to weak inducers of CYP3A may result in decreased plasma concentration of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir. 
Istodobna primjena lijeka EVOTAZ i lijekova koji su umjereni do slabi induktori CYP3A može dovesti do smanjenja plazmatskih koncentracija atazanavira i/ili kobicistata, što dovodi do gubitka terapijskog učinka i mogućeg razvoja rezistencije na atazanavir.
When compared to their single-agent profiles all findings could be attributed to either atazanavir or cobicistat. 
U usporedbi s profilima tih dvaju lijekova primijenjenih samostalno, svi su se nalazi mogli pripisati atazanaviru ili kobicistatu.
Clinically significant interactions between EVOTAZ and substrates of CYP1A2, CYP2B6, CYP2C9 or CYP2C19 are not expected. 
Ne očekuju se klinički značajne interakcije između lijeka EVOTAZ i supstrata za CYP1A2, CYP2B6, CYP2C9 ili CYP2C19.
Reversible elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT) have occurred in patients receiving atazanavir (see section 4.8). 
U bolesnika koji su primali atazanavir nastupilo je reverzibilno povišenje razine indirektnog (nekonjugiranog) bilirubina povezano s inhibicijom UDP-glukuronozil transferaze (UGT) (vidjeti dio 4.8).
Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function. 
Pokazalo se da kobicistat smanjuje procijenjeni klirens kreatinina zbog inhibicije tubularne sekrecije kreatinina, ali zapravo ne utječe na funkciju bubrežnih glomerula.
No human data on the effect of cobicistat on fertility are available. 
Nisu dostupni podaci o utjecaju kobicistata na plodnost ljudi.
HIV-1 RNA <50 copies/ml 
Virološki uspjeh HIV-1 RNK < 50 kopija/ml Razlika između liječenja
Concentrations of atazanavir given with cobicistat are expected to be increased in patients with impaired hepatic function (see sections 4.2 and 4.4). 
Očekuje se da će koncentracije atazanavira primijenjenog s kobicistatom biti povišene u bolesnika s oštećenom funkcijom jetre (vidjeti dijelove 4.2 i 4.4).
EVOTAZ is expected to increase rilpivirine plasma concentrations. 
Očekuje se da će EVOTAZ povisiti plazmatske koncentracije rilpivirina.
Concomitant use of EVOTAZ and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. 
Istodobnom primjenom EVOTAZA i kortikosteroida koji se metaboliziraju putem CYP3A (npr.flutikaznpropionata ili drugih inhalacijskih ili nazalnih kortikosteroida), ukljućujući Cushingov sindrom i adrenalnu supresiju.
Because atazanavir is a component of EVOTAZ, the combination of EVOTAZ with atorvastatin is not recommended (see section 4.5). 
Budući da je atazanavir sastavnica lijeka EVOTAZ, ne preporučuje se kombinacija lijeka EVOTAZ i atorvastatina (vidjeti dio 4.5).
Co-administration of medicinal products that are substrates of CYP3A and have narrow therapeutic indeces and for which elevated plasma concentrations are associated with serious and/or life-threatening events are contraindicated with EVOTAZ. 
Kontraindicirana je istodobna primjena lijeka EVOTAZ i lijekova koji su supstrati za CYP3A i imaju uzak terapijski indeks i čije se povišene plazmatske koncentracije povezuju s ozbiljnim i/ili po život opasnim događajima.
Some patients have reported dizziness when taking atazanavir or cobicistat, active substances of EVOTAZ. 
Neki su bolesnici prijavili omaglicu tijekom primjene atazanavira ili kobicistata, djelatnih tvari lijeka EVOTAZ.
Famotidine 20 mg twice daily (atazanavir 300 mg/ritonavir 100 mg once daily) in HIV-infected patients 
Famotidin 20 mg dvaput na dan (atazanavir 300 mg/ritonavir 100 mg jedanput na dan) u bolesnika s HIV infekcijom
The peak concentration of digoxin is increased when co-administered with cobicistat. 
Vršna koncentracija digoksina raste pri istodobnoj primjeni s kobicistatom.
Increased plasma concentrations of medicinal products that are metabolised by CYP3A, CYP2C8, CYP2D6 and/or UGT1A1 are expected when co-administered with EVOTAZ. 
Pri istodobnoj primjeni s lijekom EVOTAZ očekuju se povišene plazmatske koncentracije lijekova koji se metaboliziraju putem CYP3A, CYP2C8, CYP2D6 i/ili UGT1A1.
Each single agent produced effects on left ventricular contractility and PR prolongation at concentrations at least 35-fold higher than the free atazanavir and cobicistat concentrations at the recommended human dose (RHD) Cmax. 
Svaki je lijek zasebno utjecao na kontraktilnost lijeve klijetke i produljenje PR-intervala pri koncentracijama koje su bile najmanje 35 puta više od koncentracija slobodnog atazanavira i kobicistata pri vrijednosti Cmax koja se postiže nakon primjene preporučene doze za ljude.
Co-administration with the following medicinal products due to the potential for serious and/or lifethreatening adverse reactions (see section 4.5): colchicine, when used in patients with renal and/or hepatic impairment (antigout) (see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension (see sections 4.4 and 4.5 for co-administration for the treatment of erectile dysfunction), avanafil (PDE5 inhibitors) simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) (see section 4.5) glecaprevir/pibrentasvir fixed dose combination (see section 4.5) 
Istodobna primjena sa sljedećim lijekovima zbog mogućih ozbiljnih i/ili po život opasnih nuspojava (vidjeti dio 4.5): kolhicin, kada se koristi u bolesnika s oštećenjem bubrežne i/ili jetrene funkcije (lijek za liječenje gihta) (vidjeti dio 4.5) sildenafil - kada se koristi za liječenje plućne arterijske hipertenzije (vidjeti dijelove 4.4 i 4.5 za istodobnu primjenu kod liječenja erektilne disfunkcije), avanafil (inhibitori PDE-5) simvastatin i lovastatin (inhibitori HMG-CoA reduktaze) (vidjeti dio 4.5)
Atazanavir with cobicistat 
Atazanavir s kobicistatom
Atazanavir, a component of EVOTAZ is excreted in human milk. 
Atazanavir, sastojak lijeka EVOTAZ izlučuje se u majčino mlijeko.
Cobicistat is a strong mechanism-based CYP3A inhibitor and a weak CYP2D6 inhibitor. 
Kobicistat je snažan inhibitor CYP3A temeljeno na mehanizmu i slab inhibitor CYP2D6.
Each film-coated tablet contains 300 mg of atazanavir (as sulphate), and 150 mg cobicistat. 
Jedna filmom obložena tableta sadrži 300 mg atazanavira (u obliku atazanavirsulfata) i 150 mg kobicistata.
Voriconazole should not be co-administered with EVOTAZ unless the benefit/risk assessment justifies the use of voriconazole (see section 4.4). 
Vorikonazol se ne smije primjenjivati istodobno s lijekom EVOTAZ, osim u slučajevima kada ocjena koristi/rizika opravdava primjenu vorikonazola (vidjeti dio 4.4).
There was an increase in the maximum PR interval compared to atazanavir alone. 
Primijećeno je produljenje maksimalnog PRintervala u usporedbi s atazanavirom primijenjenim samostalno.
Co-administration of EVOTAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with the increase in grazoprevir concentrations (see section 4.3 and Table 1). 
Istodobna primjena lijeka EVOTAZ s lijekovima koji sadrže grazoprevir, uključujući fiksnu kombinaciju elbasvir/grazoprevir (koja se koristi u liječenju kronične infekcije virusom hepatitisa C), kontraindicirana je zbog povišene koncentracije grazoprevira i elbasvira u plazmi, te postoji povećan rizik povišenja vrijednosti ALT-a zbog povišene koncentracije grazoprevira (vidjeti dio 4.3 i Tablicu 1).
There are no pharmacokinetic data available for atazanavir in combination with cobicistat in patients with renal insufficiency. 
Nema dostupnih farmakokinetičkih podataka o primjeni atazanavira u kombinaciji s kobicistatom u bolesnika s insuficijencijom bubrega.
No clinically relevant pharmacokinetic differences due to gender have been identified for atazanavir or cobicistat. 
Nisu identificirane klinički značajne farmakokinetičke razlike uvjetovane spolom koje bi bile povezane s atazanavirom ili kobicistatom.
Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may decrease the clearance of atazanavir and cobicistat, resulting in increased atazanavir and cobicistat plasma concentrations (see section 4.5). 
Istodobna primjena lijeka EVOTAZ s lijekovima koji inhibiraju CYP3A može smanjiti klirens atazanavira i kobicistata, što za posljedicu može imati povišene plazmatske koncentracije atazanavira i kobicistata (vidjeti dio 4.5).
The demographic and baseline characteristics were similar between the atazanavir with cobicistat and atazanavir with ritonavir groups. 
Demografske i početne značajke bile su slične u skupini liječenoj atazanavirom i kobicistatom i onoj liječenoj atazanavirom i ritonavirom.
Atazanavir is metabolised principally by CYP3A4. 
Atazanavir se prvenstveno metabolizira putem CYP3A4.
Sofosbuvir 400 mg/velpatasvir, 100 mg/voxilaprevir 100 mg single dose* (atazanavir 300 mg with ritonavir 100 mg once daily) 
Sofosbuvir 400 mg/velpatasvir, 100 mg/voksilaprevir 100 mg u jednokratnoj dozi* (atazanavir 300 mg s ritonavirom 100 mg jednom dnevno)
These medicinal products include alfuzosin, amiodarone, astemizole, bepridil, cisapride, colchicine, dronedarone, ergot deriviatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine), lovastatin, orally administered midazolam, pimozide, quetiapine, quinidine, lurasidone, simvastatin, sildenafil (when used to treat pulmonary arterial hypertension), avanafil, systemic lidocaine, ticagrelor, terfenadine and triazolam. 
Među njih se ubrajaju alfuzosin, amiodaron, astemizol, bepridil, cisaprid, kolhicin, dronedaron, derivati ergota (npr. dihidroergotamin, ergometrin, ergotamin, metilergonovin), lovastatin, peroralno primijenjen midazolam, pimozid, kvetiapin, kinidin, lurasidon, simvastatin, sildenafil (kada se koristi za liječenje plućne arterijske hipertenzije), avanafil, sistemski lidokain, tikagrelor, terfenadin i triazolam.
Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated. 
U bolesnika koji ne podnose dozu od 150 mg triput tjedno preporučuje se daljnje smanjenje doze rifabutina na 150 mg dvaput tjedno u određene dane.
If drospirenone/ethinyloestradiol is co-administered with atazanavir/cobicistat clinical monitoring is recommended due to the potential for hyperkalemia. 
Ako se drospirenon/etinilestradiol primjeni istodobno s atazanavir/kobicistatom preporučuje se kliničko praćenje zbog moguće hiperkalemije.
NAME OF THE MEDICINAL PRODUCT EVOTAZ 300 mg/150 mg film-coated tablets atazanavir/cobicistat 
EVOTAZ 300 mg/150 mg filmom obložene tablete atazanavir/kobicistat
EVOTAZ should be used with caution in patients with mild hepatic impairment. 
EVOTAZ treba primjenjivati uz oprez u bolesnika s blagim oštećenjem jetrene funkcije.
Co-administration of boceprevir and EVOTAZ is not recommended. 
Ne preporučuje se istodobna primjena boceprevira i lijeka EVOTAZ.
Simeprevir may increase atazanavir and/or cobicistat plasma concentrations. 
Simeprevir može povisiti plazmatske koncentracije atazanavira i/ili kobicistata.
It is especially important to mention these: medicines containing ritonavir or cobicistat (booster agents) other medicines to treat HIV infection (e.g. indinavir, didanosine, tenofovir disoproxil, tenofovir alafenamide, efavirenz, etravirine, nevirapine and maraviroc) boceprevir, simeprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) sildenafil, vardenafil and tadalafil (used by men to treat impotence [erectile dysfunction]) if you are taking an oral contraceptive ("the Pill") any medicines used to treat diseases related to the acid in the stomach (e.g. antacids, H2-blockers like famotidine and proton pump inhibitors like omeprazole) disopyramide, flecainide, mexiletine, propafenone, digoxin, bosentan, amlodipine, felodipine, nicardipine, nifedipine, verapamil, diltiazem, metoprolol and timolol (medicines to lower blood pressure, to slow heart rate or to correct heart rhythm) atorvastatin, pravastatin, fluvastatin, pitavastatin and rosuvastatin (used to lower blood cholesterol) salmeterol (used to treat asthma) ciclosporin, tacrolimus and sirolimus (medicines to decrease the effects of body's immune system) certain antibiotics (rifabutin, clarithromycin) ketoconazole, itraconazole, voriconazole and fluconazole (antifungals) metformin (used to treat type 2 diabetes) warfarin, rivaroxaban and dabigatran (anticoagulants, used to reduce blood clots) irinotecan, dasatinib, nilotinib, vinblastine and vincristine (used to treat cancer) trazodone (used to treat depression) 
Osobito je važno da spomenete sljedeće: lijekove koji sadrže ritonavir ili kobicistat (pojačivače) druge lijekove za liječenje HIV infekcije (npr. indinavir, didanozin, tenofovirdizoproksil, tenofoviralafenamid, efavirenz, etravirin, nevirapin i maravirok) boceprevir, simeprevir i sofosbuvir/velpatasvir/voksilaprevir (koji se koriste u liječenju hepatitisa C) sildenafil, vardenafil i tadalafil (uzimaju ih muškarci za liječenje impotencije [erektilne disfunkcije]) ako uzimate oralnu kontracepciju ("pilule") bilo koji lijek za liječenje bolesti povezanih s kiselinom u želucu (npr. antacide, H2blokatore poput famotidina i inhibitore protonske pumpe poput omeprazola) dizopiramid, flekainid, meksiletin, propafenon, digoksin, bosentan, amplodipin, felodipin, nikardipin, nifedipin, verapamil, diltiazem, metoprolol i timolol (lijekovi za snižavanje krvnog tlaka, usporavanje rada srca ili ispravljanje srčanog ritma) atorvastatin, pravastatin, fluvastatin, pitavastatin i rosuvastatin (primjenjuju se za snižavanje razine kolesterola u krvi) salmeterol (primjenjuje se za liječenje astme) ciklosporin, takrolimus i sirolimus (lijekovi za smanjenje učinaka imunosnog sustava tijela) određene antibiotike (rifabutin, klaritromicin) ketokonazol, itrakonazol, vorikonazol i flukonazol (lijekovi za liječenje gljivičnih infekcija)
Common (may affect up to 1 in 10 people) increased appetite, dysgeusia (impairment of the sense of taste), dry mouth headache, dizziness insomnia (difficulty sleeping), abnormal dreams, somnolence (sleepiness) vomiting, diarrhoea, abdominal pain (stomach pain of discomfort), dyspepsia (indigestion), bloated or distended tummy (abdomen), flatulence (wind) hyperbilirubinaemia (increased levels of bilirubin in the blood) rash fatigue (extreme tiredness) 
Često (mogu se javiti u do 1 na 10 osoba) pojačan tek, disgeuzija (poremećaj osjeta okusa), suha usta glavobolja, omaglica nesanica (poteškoće sa spavanjem), neuobičajeni snovi, somnolencija (pospanost) povraćanje, proljev, bol u abdomenu (bol ili nelagoda u trbuhu), dispepsija (probavne tegobe), nadutost ili rastezanje trbuha, flatulencija (vjetrovi) hiperbilirubinemija (povišene razine bilirubina u krvi) osip iscrpljenost (izrazit umor)
The mechanism of interaction is inhibition of CYP2D6 by cobicistat. 
Mehanizam interakcije je inhibicija CYP2D6 koju uzrokuje kobicistat.
Uncommon (may affect up to 1 in 100 people) torsade de pointes (life threatening irregular heart beat) hypersensitivity (allergic reaction) anorexia (loss of appetite), weight loss, weight gain depression, anxiety, sleep disorder disorientation, amnesia (loss of memory) peripheral neuropathy (numbness, weakness, tingling or pain in the arms and legs) syncope (fainting), hypertension (high blood pressure) dyspnoea (shortness of breath) pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores) hepatitis (inflammation of the liver) angioedema (severe swelling of the skin and other tissues most often the lips or the eyes) urticaria (itchy rash), alopecia (unusual hair loss or thinning), pruritus (itching) muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) nephrolithiasis (formation of kidney stones), interstitial nephritis (kidney inflammation), hematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination), chronic kidney disease (how well your kidneys work) gynaecomastia (breast enlargement in men) chest pain, malaise (generally feeling unwell), fever asthenia (unusual tiredness or weakness) serious skin rashes (allergic reactions including rash, a high temperature, increased levels of liver enzymes seen in blood tests, an increase in a type of white blood cell [esosinophilia] and/or enlarged lymph nodes) (see section 2) gallbladder disorders (gallstones and gallbladder inflammation) 
Manje često (mogu se javiti u do 1 na 100 osoba) torsade de pointes (po život opasna nepravilnost srčanog ritma) preosjetljivost (alergijska reakcija) anoreksija (gubitak teka), gubitak tjelesne težine, povećanje tjelesne težine depresija, tjeskoba, poremećaj spavanja dezorijentacija, amnezija (gubitak pamćenja) periferna neuropatija (utrnulost, slabost, trnci ili bol u rukama i nogama) sinkopa (nesvjestica), hipertenzija (visok krvni tlak) dispneja (nedostatak zraka) pankreatitis (upala gušterače), gastritis (upala želuca), aftozni stomatitis (vrijedovi i afte u ustima) hepatitis (upala jetre) angioedem (teško oticanje kože i drugih tkiva , najčešće usana i očiju) urtikarija (osip koji svrbi), alopecija (neuobičajeno opadanje ili stanjivanje kose), pruritus (svrbež) mišićna atrofija (smanjenje mišića), artralgija (bol u zglobovima), mialgija (bol u mišićima) nefrolitijaza (stvaranje bubrežnih kamenaca), intersticijski nefritis (upala bubrega), hematurija (krv u mokraći), proteinurija (višak proteina u mokraći), polakizurija (učestalo mokrenje), kronična bubrežna bolest (kako dobro rade vaši bubrezi) ginekomastija (povećanje grudi u muškaraca) bol u prsištu, malaksalost (opće loše osjećanje), vrućica astenija (neuobičajen umor ili slabost) ozbiljni kožni osipi (alergijske reakcije koje uključuju osip, povišenu tjelesnu temperaturu, povišene razine jetrenih enzima u nalazima krvnih pretraga, povišen broj određene vrste bijelih krvnih stanica [eozinofilija] i/ili povećane limfne čvorove) (pogledajte dio 2.)
Cobicistat does not select any HIV resistance mutations, due to its lack of antiviral activity. 
Budući da kobicistat nema antivirusnu aktivnost, on ne izdvaja mutacije HIV virusa koje uzrokuju rezistenciju.
25-O-desacetyl-rifabutin AUC 
25-O-dezacetil-rifabutin AUC ↑990%
Atazanavir, an active component of EVOTAZ, has been detected in human milk. 
Atazanavir, djelatna tvar lijeka EVOTAZ pronađena je u majčinom mlijeku.
Midazolam and triazolam are extensively metabolized by CYP3A4. 
Midazolam i triazolam opsežno se metaboliziraju putem CYP3A4.
Cobicistat is a strong mechanism-based CYP3A inhibitor and is a CYP3A substrate. 
Kobicistat je snažan inhibitor CYP3A temeljeno na mehanizmu i supstrat za CYP3A.
No significant effect on atazanavir concentrations was observed. 
Nije opažen značajan učinak na koncentracije atazanavira.